HUE045046T2 - Aminooxi-csoportot tartalmazó oligoszacharidok és azok konjugátumai - Google Patents

Aminooxi-csoportot tartalmazó oligoszacharidok és azok konjugátumai

Info

Publication number
HUE045046T2
HUE045046T2 HUE11188504A HUE11188504A HUE045046T2 HU E045046 T2 HUE045046 T2 HU E045046T2 HU E11188504 A HUE11188504 A HU E11188504A HU E11188504 A HUE11188504 A HU E11188504A HU E045046 T2 HUE045046 T2 HU E045046T2
Authority
HU
Hungary
Prior art keywords
oligosaccharides
conjugates
aminooxy group
aminooxy
group
Prior art date
Application number
HUE11188504A
Other languages
English (en)
Inventor
Yunxiang Zhu
Seng H Cheng
Canwen Jiang
Luis Z Avila
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of HUE045046T2 publication Critical patent/HUE045046T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HUE11188504A 2007-01-18 2008-01-18 Aminooxi-csoportot tartalmazó oligoszacharidok és azok konjugátumai HUE045046T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88547107P 2007-01-18 2007-01-18

Publications (1)

Publication Number Publication Date
HUE045046T2 true HUE045046T2 (hu) 2019-12-30

Family

ID=39473250

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE11188506A HUE036140T2 (hu) 2007-01-18 2008-01-18 Aminooxi-csoportot tartalmazó oligoszacharidok és ezek konjugátjai
HUE11188504A HUE045046T2 (hu) 2007-01-18 2008-01-18 Aminooxi-csoportot tartalmazó oligoszacharidok és azok konjugátumai
HUS2200055C HUS2200055I1 (hu) 2007-01-18 2022-12-19 Aminooxi-csoportot tartalmazó oligoszacharidok és konjugátumaik

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11188506A HUE036140T2 (hu) 2007-01-18 2008-01-18 Aminooxi-csoportot tartalmazó oligoszacharidok és ezek konjugátjai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2200055C HUS2200055I1 (hu) 2007-01-18 2022-12-19 Aminooxi-csoportot tartalmazó oligoszacharidok és konjugátumaik

Country Status (19)

Country Link
US (5) US8759501B2 (hu)
EP (5) EP3597655B1 (hu)
JP (6) JP5999867B2 (hu)
CN (2) CN102978185B (hu)
CA (1) CA2675968C (hu)
CY (2) CY1119954T1 (hu)
DK (3) DK2457920T3 (hu)
ES (3) ES2744574T3 (hu)
FR (1) FR22C1061I2 (hu)
HR (3) HRP20130744T1 (hu)
HU (3) HUE036140T2 (hu)
IL (3) IL243117B2 (hu)
LT (2) LT2457919T (hu)
NL (1) NL301210I2 (hu)
NO (2) NO2457920T3 (hu)
PL (3) PL2457919T3 (hu)
PT (3) PT2121713E (hu)
SI (2) SI2457919T1 (hu)
WO (1) WO2008089403A2 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
DK2457920T3 (en) * 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP3608330B1 (en) * 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
EP2448600B1 (en) 2009-07-03 2016-03-30 INSERM - Institut National de la Santé et de la Recherche Médicale Compounds targeting the cation-independent mannose 6-phosphate receptor
ES2590679T3 (es) * 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
EP3093029A1 (en) * 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011163568A1 (en) * 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
WO2012082635A1 (en) * 2010-12-13 2012-06-21 Ancora Pharmaceuticals, Inc. Synthetic oligosaccharide group a streptococcus
DK2665814T3 (en) 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
TWI821227B (zh) 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
CA3118909A1 (en) * 2018-11-08 2020-05-14 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof
CN115335081A (zh) 2020-02-07 2022-11-11 诺华股份有限公司 靶向血浆蛋白降解
TW202142264A (zh) 2020-02-08 2021-11-16 美商健臻公司 治療龐貝氏症的組成物及方法
WO2021257409A1 (en) 2020-06-14 2021-12-23 Genzyme Corporation Compositions and methods for treating late-onset pompe disease

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2940845B1 (de) 1979-10-09 1980-06-26 Ford Werke Ag Kreiselpumpendichtung,insbesondere fuer Kuehlwasserpumpen in Kraftfahrzeugen
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5212298A (en) 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5583042A (en) 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
AU1580292A (en) * 1991-03-13 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
FR2721612B1 (fr) 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPO190596A0 (en) 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
ES2335557T3 (es) 1997-01-21 2010-03-29 Sanofi Pasteur Conjugados de peptido-polisacarido.
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
DE69835367T2 (de) 1997-10-29 2007-08-02 Genzyme Corp., Framingham Gentherapie für gaucher-krankheit
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6538117B1 (en) 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
AU771330B2 (en) * 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
US6399575B1 (en) 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
WO2000075105A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001238346A1 (en) 2000-02-15 2001-08-27 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001280035A1 (en) 2000-07-26 2002-02-05 Ramot University Authority For Applied Research And Industrial Development Ltd. Intracellular delivery system for protein phosphatases and other polypeptides
EP1315559B1 (en) 2000-08-18 2006-03-22 Massachusetts Institute Of Technology Apparatus and methods for the automated synthesis of oligosaccharides
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
EP1385873A2 (en) 2001-05-07 2004-02-04 Supratek Pharma, Inc. A ligand for enhancing oral and cns delivery of biological agents
JP5038582B2 (ja) 2001-07-16 2012-10-03 ジェンザイム・コーポレーション Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
TWI295483B (en) 2002-01-31 2008-04-01 Sumitomo Chemical Co 3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same
AU2003219796A1 (en) 2002-02-20 2003-09-09 Beth Israel Deaconess Medical Center Conjugates comprising a biodegradable polymer and uses therefor
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
ES2214166T1 (es) * 2002-09-11 2004-09-16 Fresenius Kabi Deutschland Gmbh Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
AU2003253399B2 (en) 2002-09-11 2010-10-14 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP2007501811A (ja) 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
US7691826B2 (en) 2003-08-12 2010-04-06 Lipoxen Technologies Limited Polysialic acid derivatives
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
EP1713508A2 (en) * 2004-01-29 2006-10-25 Biosynexus Incorporated Use of amino-oxy functional groups in the preparation of vaccine conjugates
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
EP1740204B1 (en) 2004-04-01 2018-03-14 Chiesi Farmaceutici S.p.A. Medicinal use of alpha-mannosidase
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
DK2457920T3 (en) 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates

Also Published As

Publication number Publication date
EP4293112A3 (en) 2024-03-13
FR22C1061I2 (fr) 2023-11-17
PL2121713T3 (pl) 2013-11-29
PL2457919T3 (pl) 2019-12-31
CA2675968A1 (en) 2008-07-24
NO2022056I1 (no) 2022-12-09
HRP20130744T1 (hr) 2013-10-11
ES2744574T3 (es) 2020-02-25
JP2020185011A (ja) 2020-11-19
DK2121713T3 (da) 2013-06-24
ES2656314T3 (es) 2018-02-26
HRP20191562T1 (hr) 2019-11-29
EP2121713B1 (en) 2013-06-12
US20170014520A1 (en) 2017-01-19
US9469850B2 (en) 2016-10-18
CN102978185B (zh) 2015-02-11
PL2457920T3 (pl) 2018-03-30
NL301210I1 (nl) 2022-12-21
EP3597655A1 (en) 2020-01-22
JP2018109194A (ja) 2018-07-12
US20100047225A1 (en) 2010-02-25
WO2008089403A2 (en) 2008-07-24
US20220204963A1 (en) 2022-06-30
PT2121713E (pt) 2013-06-25
US8759501B2 (en) 2014-06-24
WO2008089403A3 (en) 2008-11-13
JP6039625B2 (ja) 2016-12-07
EP2457919B1 (en) 2019-06-05
ES2417146T3 (es) 2013-08-06
EP4293112A2 (en) 2023-12-20
JP2015078360A (ja) 2015-04-23
US20150050262A1 (en) 2015-02-19
LT2457920T (lt) 2018-02-12
CN102978185A (zh) 2013-03-20
HUS2200055I1 (hu) 2023-01-28
PT2457919T (pt) 2019-09-20
CA2675968C (en) 2019-05-21
HRP20180076T1 (hr) 2018-02-23
IL199925A (en) 2017-09-28
LT2457919T (lt) 2019-09-25
US10907142B2 (en) 2021-02-02
IL222792A0 (en) 2012-12-31
DK2457919T3 (da) 2019-09-16
EP2457920B1 (en) 2017-10-25
IL243117B2 (en) 2023-03-01
EP2457919A1 (en) 2012-05-30
SI2457920T1 (en) 2018-02-28
HUE036140T2 (hu) 2018-06-28
NL301210I2 (nl) 2023-02-02
CN101631794A (zh) 2010-01-20
JP6309592B2 (ja) 2018-04-11
CY1122452T1 (el) 2021-01-27
JP2022137232A (ja) 2022-09-21
IL243117A (hu) 2016-01-31
EP2457920A1 (en) 2012-05-30
SI2457919T1 (sl) 2019-10-30
CN101631794B (zh) 2013-01-02
EP3597655B1 (en) 2023-08-02
JP2017052962A (ja) 2017-03-16
IL243117B (en) 2022-11-01
PT2457920T (pt) 2018-01-23
FR22C1061I1 (fr) 2023-02-03
US20200010825A1 (en) 2020-01-09
JP5999867B2 (ja) 2016-09-28
CY1119954T1 (el) 2018-12-12
EP2121713A2 (en) 2009-11-25
DK2457920T3 (en) 2018-01-22
IL199925A0 (en) 2010-04-15
JP2010516257A (ja) 2010-05-20
NO2457920T3 (hu) 2018-03-24

Similar Documents

Publication Publication Date Title
HUS2200055I1 (hu) Aminooxi-csoportot tartalmazó oligoszacharidok és konjugátumaik
IL283205A (en) Attached medicinal substance that binds to cells, preparations containing them and their uses
HUS2100013I1 (hu) Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények
PT1988910T (pt) Acriloiloxietilfosforilcolina contendo conjugados de polímeros e sua preparação
ZA201001206B (en) Saccharide-containing protein conjugates and uses thereof
HK1149034A1 (en) Immunoconjugates targeting cd138 and uses thereof cd138
ZA201004609B (en) Polypeptide-nucleic acid conjugates and uses thereof
IL189245A0 (en) Interleukin-1 conjugates and uses thereof
ZA201103043B (en) Etoposide and doxorubicin conjugates for drug delivery
EP2370472A4 (en) LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
ZA201201218B (en) 3-polylysine conjugates and the use thereof
IL218869A (en) Oligomer-calcimimetic couplings and preparations containing them
SI2121713T1 (sl) Oligosaharidi, ki obsegajo aminooksi skupino, in njihovi konjugati
IL202849A0 (en) Targeting conjugates comprising active agent encapsulated in cyclodextrin-containing polymers